Increasing fluroquinolone susceptibility and genetic diversity of ESBL-producing E. coli from the lower respiratory tract during the COVID-19 pandemic

Katja Hrovat (Avtor), Katja Seme (Avtor), Jerneja Ambrožič (Avtor)

Povzetek

Lower respiratory tract infections (LRTIs) are the fourth leading cause of death worldwide, among which Escherichia coli (E. coli) pneumonia is considered a rare phenomenon. Treatment options for LRTIs have become limited, especially for extended-spectrum β-lactamase-producing E. coli (ESBL-EC), which are usually resistant to other groups of antimicrobials as well. The aim of our study was to compare the phenotypic resistance profiles and genotypes of ESBL-EC isolates associated with LRTIs before (pre-COVID-19) and during (COVID-19) the COVID-19 pandemic. All isolates were screened for antimicrobial resistance genes (ARGs) and virulence-associated genes (VAGs) and assigned to phylogenetic groups, sequence types and clonal groups by PCR. During the pandemic, a significantly lower proportion of ciprofloxacin-, levofloxacin- and trimethoprim-sulfamethoxazole-resistant ESBL-EC isolates was retrieved from lower respiratory tract (LRT) samples. PCR-based genotypization revealed greater clonal diversity and a significantly lower proportion of isolates with bla$_{TEM}$, aac(6′)-Ib-cr and qacE∆1 genes. In addition, a higher proportion of isolates with the integrase gene int1 and virulence genes sat and tsh was confirmed. The lower prevalence of fluoroquinolone resistance and greater genetic diversity of ESBL-EC isolated during the COVID-19 period may have been due to the introduction of new bacterial strains into the hospital environment, along with changes in clinical establishment guidelines and practices.

Ključne besede

odpornost proti protimikrobnim učinkovinam;Escherichia coli;β-laktamaze z razširjenim spektrom delovanja;spodnji dihalni trakt;COVID-19;antimicrobial resistance;extended-spectrum β-lactamases;lower respiratory tract;

Podatki

Jezik:	Angleški jezik
Leto izida:	2024
Tipologija:	1.01 - Izvirni znanstveni članek
Organizacija:	UL BF - Biotehniška fakulteta
UDK:	615
COBISS:	205359875
ISSN:	2079-6382
Št. ogledov:	21
Št. prenosov:	10
Ocena:	0 (0 glasov)
Metapodatki:

Ostali podatki

Sekundarni jezik:	Slovenski jezik
Sekundarne ključne besede:	odpornost proti protimikrobnim učinkovinam;Escherichia coli;β-laktamaze z razširjenim spektrom delovanja;spodnji dihalni trakt;COVID-19;
Vrsta dela (COBISS):	Članek v reviji
Strani:	str. 1-14
Letnik:	ǂVol. ǂ13
Zvezek:	ǂIss. ǂ9
Čas izdaje:	2024
DOI:	10.3390/antibiotics13090797
ID:	26444519